Email This Article

Another Study From ImClone Shows Mixed Results for Erbitux
By Adam Feuerstein
05/19/02 - 03:55 PM EDT
A phase III trial for head and neck cancer shows promise, but misses clinical goal.
Recipient's Email Address(es)
(Separate multiple addresses with a comma)
Your Email Address
Send a copy to myself
Your Message (optional)

Privacy Policy

The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.

Dow Jones S&P 500 NASDAQ 10-Year Note
10,388.90 1,105.98 2,194.35 34.83
Oil *
77.74
UP
22.75
UP
6.06
UP
21.21
UP
1.03
10 Yr
3.48%
SPDR Gold
113.75
+0.22%
+0.55%
+0.98%
+3.05%
Data delayed 20 minutes

Brokerage Partners